Work

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts Brachyury is a tumor-associated antigen and transcription factor that drives the epithelial-to-mesenchymal transition in human carcinomas. This Phase I study assessed whether patients with advanced cancer or chordoma, a rare tumor of the notochord that overexpresses brachyury, can

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p132

Authors: Christopher R Heery, Renee Donahue, Lauren Lepone, Italia Grenga, Jacob Richards, Simon Metenou, Romaine I Fernando, Ulrike Dirmeier, Harpreet Singh, Ravi Madan, James L Gulley, Jeffrey Schlom

Institutions: National Cancer Institute, Center for Cancer Research, Bavarian Nordic (Germany), National Institutes of Health

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2176056554

Cites:

Cited by: 5

Related to: 10